Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

Monday, August 10, 2026Gwendolyn WuView original

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.

Read the full article on the original site.